D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
GRAIL, Inc. (NASDAQ:GRAL), a medical laboratory services provider with a market capitalization of $1.48 billion, announced the results of its Annual Meeting of Stockholders held on May 29, 2025. According to InvestingPro analysis, the company’s stock is currently trading near its Fair Value. The meeting saw a quorum with 29,682,974 shares represented, out of the 35,296,858 shares eligible to vote as of the March 31, 2025 record date.
The first proposal at the meeting was the election of a Class I Director who will serve until the 2028 Annual Meeting of Stockholders. The elected director, William Chase, received 19,046,188 votes in favor, with 1,234,461 withheld votes and 9,402,325 broker non-votes.
The second proposal, which concerned the ratification of Ernst & Young LLP as GRAIL’s independent registered public accounting firm for the fiscal year ending December 31, 2025, was also approved by stockholders. The proposal received 29,086,225 votes for, 66,878 against, and 529,871 abstentions, with no broker non-votes.
The voting results were disclosed in a filing with the Securities and Exchange Commission and were part of the company’s Definitive Proxy Statement filed on April 15, 2025. These results reflect the decisions made by the stockholders on matters that impact the governance and oversight of the company.
GRAIL, Inc., incorporated in Delaware and headquartered in Menlo Park, California, is recognized under the SIC code for Medical (TASE:BLWV) Laboratories. The company’s common stock is traded on The Nasdaq Global Select Market under the ticker symbol GRAL.
This report is based on information contained in a press release statement.
In other recent news, GRAIL, Inc. reported its first-quarter financial results for 2025, revealing a revenue increase of 19% year-over-year to $31.8 million, driven by strong demand for its Galleri test. Despite surpassing earnings per share expectations with a reported EPS of -$3.10 against a forecast of -$4.26, the company faced a net loss of $106.2 million, although this marked a 51% improvement from the previous year. The company’s cash position stands at $677.9 million, with a projected cash burn for the year not exceeding $320 million. Canaccord Genuity analyst Kyle Mikson raised the price target for GRAIL to $43, maintaining a Buy rating, citing the company’s growth potential in the multi-cancer early detection market. GRAIL also launched an enhanced version of its Galleri test, which contributed to a 24% increase in screening revenue. The company remains optimistic about future growth, reaffirming its guidance for 2025 with anticipated U.S. Galleri revenue growth of 20-30%. GRAIL is on track to release data from its PATHFINDER 2 study by the end of 2025 and plans to submit findings to the FDA in 2026. These developments are expected to support GRAIL’s position in the market and validate the effectiveness of the Galleri test.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.